Described as radically changing proteomics to impact/ transform Healthcare by transforming how diseases were detected and diagnosed. Only briefly BBIR-involved soon after founding, building on a solid foundation of aptamer research SomaLogic scientists developed a new proteomics technology designed to overcome significant challenges of current technologies and which has multiple applications across the biological and medical sciences. Going public in May 2021, SomaLogic (NASDAQ:SLGC) is a biotechnology company developing proteomics systems and diagnostics based on the company's proprietary Slow Off-rate Modified Aptamer ("SOMAmer") technology. The company's aptamer arrays are structured to enable researchers --and ultimately clinicians--to measure large numbers of proteins simultaneously, effectively providing the foundation for new insights into disease and health. With the firm's mission desicribed as leveraging their proprietary technology to discover, develop and commercialize revolutionary new life science research tools and breakthrough clinical diagnostic products that will transform healthcare, the firm offers several products to researchers: SOMAscan protein biomarker discovery tool, reagents that bind to proteins, and SomaSuite: a software platform allowing direct access into the proteomic data generated by SOMAscan, the firm has an extensive intellectual property (IP) estate of issued patents and pending patent applications providing the firm global protection in the major diagnostic and pharmaceutical markets for nucleic acid based chemistries and the development and use of the companys proprietary SOMAmer® protein binding reagents.
